spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  polymerase inhibitor 

 HSMN NewsFeed - 3 Nov 2021
Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 3 Apr 2017
BioCryst Announces Mundipharma Receives Approval for Mundesine(R) in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Dec 2016
Foundation Medicine Receives FDA Approval of FoundationFocus(TM) CDxBRCA as a Companion Diagnostic for Rubraca(TM) (rucaparib) for the Treatment of Women with Ovarian Cancer
Diagnostics Oncology FDA
 HSMN NewsFeed - 23 Sep 2016
AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(R) (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 15 Apr 2016
AbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
Biopharmaceuticals
 HSMN NewsFeed - 15 Apr 2016
AbbVie Announces Real-World Data with VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA(R) (dasabuvir tablets) from Large German Hepatitis C-Registry
Biopharmaceuticals
 HSMN NewsFeed - 16 Jan 2015
European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA(R) (dasabuvir tablets) for the Treatment of Chronic Hepatitis C
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Mar 2014
Novira Names Christian S. Schade Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jan 2014
European Commission Grants Marketing Authorization for Gilead’s Sovaldi(R) (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Dec 2013
U.S. Food and Drug Administration Approves Gilead’s Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Mar 2013
Novira Therapeutics Completes $25 Million Series A Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 18 May 2011
Abbott Receives FDA Approval for Molecular Test for Hepatitis C
Diagnostics FDA
 HSMN NewsFeed - 2 Nov 2007
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Biopharmacetuicals
 HSMN NewsFeed - 30 Oct 2007
Significant New Data on Roche's PEGASYS(R) and Hepatitis C Pipeline Compounds to be Featured at 58th Annual AASLD Meeting
Biopharmaceuticals
 HSMN NewsFeed - 24 Oct 2007
R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Sep 2007
Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
Biopharmaceuticals
 HSMN NewsFeed - 20 Sep 2007
Shareholders Approve Inhibitex Acquisition of FermaVir
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 13 Jul 2007
Valopicitabine Development Program Placed on Clinical Hold in the United States
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2007
FDA Grants Fast Track Status for HCV-796 for Treatment of Hepatitis C Virus Infection
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Apr 2007
Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 27 Nov 2006
Biota and Boehringer Ingelheim Complete US$102 Million License for HCV Program
Biopharmaceuticals Licensing
 HSMN NewsFeed - 27 Oct 2006
Idenix Announces New 24-Week Data From A Phase IIb Clinical Trial Of Valopicitabine Plus Pegylated Interferon in Treatment Naive Genotype-1 Hepatitis C Patients
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2006
Roche Oral Polymerase Inhibitor R1626 Shows Strong Antiviral Activity in Chronic Hepatitis C Patients in Early Trial
Biopharmaceuticals
 HSMN NewsFeed - 13 Oct 2006
Roche Advances Oral Polymerase Inhibitor into Phase II Study in Patients with Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 13 Sep 2006
Bristol-Myers Squibb Company and Medivir AB Announce Worldwide Collaboration to Develop and Commercialize MIV-170 for the Treatment of HIV-1 Infection in Adults
Biopharmaceuticals HIV/AIDS Licensing
Return to NewsFeed  

 Additional items found! 10

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 10 additional stories matching:
polymerase inhibitor
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.